Non-steroidal anti-inflammatory drugs for pain in women with endometriosis

Allen, Claire; Hopewell, Sally; Prentice, Andrew; Gregory, Daisy

doi:10.1002/14651858.cd004753.pub2

Cited by 43 publications

(30 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…''Information was extracted from each included trial on: (1) characteristics of trial participants (including age, stage and severity of disease, and method of diagnosis), and the trial's inclusion and exclusion criteria; (2) type of intervention (including type, dose, duration and frequency of the NSAID [non-steroidal anti-inflammatory drug]; versus placebo or versus the type, dose, duration and frequency of another NSAID; or versus another pain management drug; or versus no treatment); (3) type of outcome measure (including the level of pain reduction, improvement in quality of life score (using a validated scale), effect on daily activities, absence from work or school, length of follow up, unintended effects of treatment, number of women requiring more invasive treatment).'' [83] Explanation. It is important for readers to know what information review authors sought, even if some of this information was not available [84].…”

Section: Item 11: Data Itemsmentioning

confidence: 99%

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

Liberati

Altman

Tetzlaff

et al. 2009

Journal of Clinical Epidemiology

13,610

10,948

View full text Add to dashboard Cite

Systematic reviews and meta-analyses are essential to summarize evidence relating to efficacy and safety of health care interventions accurately and reliably. The clarity and transparency of these reports, however, is not optimal. Poor reporting of systematic reviews diminishes their value to clinicians, policy makers, and other users. Since the development of the QUOROM (QUality Of Reporting Of Meta-analysis) Statement--a reporting guideline published in 1999--there have been several conceptual, methodological, and practical advances regarding the conduct and reporting of systematic reviews and meta-analyses. Also, reviews of published systematic reviews have found that key information about these studies is often poorly reported. Realizing these issues, an international group that included experienced authors and methodologists developed PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) as an evolution of the original QUOROM guideline for systematic reviews and meta-analyses of evaluations of health care interventions. The PRISMA Statement consists of a 27-item checklist and a four-phase flow diagram. The checklist includes items deemed essential for transparent reporting of a systematic review. In this Explanation and Elaboration document, we explain the meaning and rationale for each checklist item. For each item, we include an example of good reporting and, where possible, references to relevant empirical studies and methodological literature. The PRISMA Statement, this document, and the associated Web site (http://www.prisma-statement.org/) should be helpful resources to improve reporting of systematic reviews and meta-analyses.

show abstract

Section: Item 11: Data Itemsmentioning

confidence: 99%

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

Liberati

Altman

Tetzlaff

et al. 2009

Journal of Clinical Epidemiology

13,610

10,948

View full text Add to dashboard Cite

show abstract

“…Specific drugs for the management of endometriosis include the anti-inflammatory drugs, oral contraceptive, intrauterine contraceptive device, and gonadotrophin releasing-hormone agonists alone or with estrogen add-back therapy [79,82]. Specific drugs for chronic pain (eg, gabapentin, pregabalin, and amitriptyline) also can be effective [83].…”

Section: Management Of Hyperalgesiamentioning

confidence: 99%

Endometriosis and Abdominal Myofascial Pain in Adults and Adolescents

Jarrell

2011

Curr Pain Headache Rep

View full text Add to dashboard Cite

Endometriosis and myofascial pain are common disorders with significant impact on quality of life. Increasingly, these conditions are being recognized as highly interconnected through processes that have been described for more than a century. This review is directed to this interconnection through a description of the relationships of endometriosis to proposed mechanisms of pain and chronic pain physiology; the clinical assessment of myofascial representations of this pain; and an approach to the management of these interconnected disorders.

show abstract

“…Воспалительный процесс в эндометриоидных тканях усиливает продукцию цитокинов (IL-1β, TNF-α) моноци-тами и макрофагами, что также способствует продукции ПГ Е 2 в этой ткани [3]. Кроме того, показано, что ароматаза не только присутству-ет в эндометриоидных гетеротопиях, эутопиче-ском эндометрии больных эндометриозом, но и ее экспрессия повышается под воздействием цитокинов, находящихся в перитонеальной жидкости [10]. Таким образом, локальная про-дукция эстрогенов и ПГ Е 2 усиливается ком-плексом молекулярных взаимоотношений по механизму обратной связи [11].…”

Section: The Efficacy Of Selective Cyclooxygenase 2 Inhibitors In Theunclassified

“…Вероятно, это связано с меньшими, по сравнению с НПВС ингибиторами ЦОГ-1 и ЦОГ-2, анальгетически-ми эффектами. К тому же появился ряд статей, указывающих, что длительное или неконтро-лируемое использование селективных НПВС может приводить к нелетальным инфарк там, тромбозам [9,10,20] [22]. В 2008 г. группа ис-следователей под руководством C. Olivares на основании рандомизированного исследования установила опти мальную дозировку целекок-сиба 100 мг [23].…”

Section: The Efficacy Of Selective Cyclooxygenase 2 Inhibitors In Theunclassified

The efficacy of selective cyclooxygenase 2 inhibitors in the treatment of genital endometriosis

et al. 2018

View full text Add to dashboard Cite

External genital endometriosis is characterized by the processes of angiogenesis, neurogenesis, impaired apoptosis, local inflammation of the tissues, secretion of estradiol, and cell proliferation. In a similar manner, prostaglandin E2 affects tissues. The safest drugs that overwhelm COX-2 activity and inhibit the expression of prostaglandin E2 are selective COX-2 inhibitors. As a mediator of inflammation, prostaglandin E2 is involved in all inflammatory processes. It induces the expression of local P450 aromatase and the anti-apoptotic gene Bcl-2. E2 also possesses immunosuppressive-mediated activity and inhibits the synthesis of cytokines IFNγ, TNFα, and IL-12, IL-1β-mediated expression of chemokines, the proliferation of T- and B-cells and reduces the cytotoxic activity of NK cells, creating a background of the immunosuppressive characteristic of endometriosis [1–3]. This study included 100 patients of reproductive age (aged 22-35 years) with a confirmed diagnosis of external genital endometriosis of degree II–IV. Fifty patients received 100 mg of celecoxib in monotherapy and in combination with 2 mg of dienoguest. The control group included 50 people receiving monotherapy with 2 mg of dienogest. The effectiveness of therapy was assessed using the visual analog scale (VAS) and on the basis of the dynamics of algodismenorrhea, pain during coitus, clinical examination, and the patient’s subjective assessment of the degree of irritability and severity of depressive syndrome. The effectiveness of the treatment was evaluated according to MRI and ultrasound of the pelvic organs throughout the study. To control for possible complications of the therapy, the patients performed a comprehensive dynamic survey assessing the indicators of general blood analysis and the blood coagulation system. In the group with the combined application of celecoxib and dienoguest, a clinically significant reduction in pain syndrome and a decrease in the degree of irritability and depressive syndrome were noted relative to the control group. No side effects of celecoxib on the body systems were identified throughout the study. Thus, celecoxib can be recommended as a safe and effective combination therapy for endometriosis.

show abstract

Non-steroidal anti-inflammatory drugs for pain in women with endometriosis

Cited by 43 publications

References 15 publications

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration

Endometriosis and Abdominal Myofascial Pain in Adults and Adolescents

The efficacy of selective cyclooxygenase 2 inhibitors in the treatment of genital endometriosis

Contact Info

Product

Resources

About